Sangamo BioSciences reported $0 in Stock for its fiscal quarter ending in March of 2022.





Stock Change Date
Alnylam Pharmaceuticals USD 105.91M 8.8M Sep/2026
Amgen USD 6.39B 169M Sep/2026
Bayer EUR 11.97B 43M Jun/2026
BioCryst Pharmaceuticals USD 13.74M 7.68M Sep/2026
Biogen USD 2.22B 159.9M Sep/2026
BioMarin Pharmaceutical USD 1.8B 13.54M Sep/2026
Cipla INR 67.78B 1.82B Sep/2026
Clal Biotechnology ILS 4.44M 0 Mar/2021
CSL USD 6.47B 327M Jun/2025
Gilead Sciences USD 1.9B 57M Sep/2026
GlaxoSmithKline GBP 6.28B 125M Jun/2026
Grifols EUR 3.56B 63.19M Dec/2024
Ionis Pharmaceuticals USD 28.58M 22.26M Sep/2026
J&J USD 15.38B 233M Sep/2026
Karyopharm Therapeutics USD 4.04M 72K Dec/2025
Merck USD 6.16B 43M Sep/2026
Novartis USD 6.1B 116M Sep/2026
Omeros USD 712K 266K Sep/2021
Pfizer USD 10.02B 77M Sep/2026
Roche Holding CHF 7.6B 9M Jun/2025
Sanofi EUR 24.12B 620M Jun/2026
Sarepta Therapeutics USD 876.12M 28.15M Sep/2026
Ultragenyx Pharmaceutical USD 59M 0 Sep/2026
Vertex Pharmaceuticals USD 2.25B 480.2M Sep/2026